




Hematopoietic Stem Cell Transplant in Puerto Rico

Alexis M. Cruz Chacón, MD FACP Hematology and Medical Oncology Blood and Marrow Transplantation



# **How a HSCT Works?**




# Why to perform a HSCT?




Allow administration of high dose antineoplastic therapy, avoiding prolonged or irreversible myelosupression through administration of rescue HSCs from patient.






Replace a hematopoietic system that is deficient, insufficient or neoplastic for a normal one from a healthy donor.






# Number of Autologous HCTs in the U.S. by Selected Disease





# Number of Allogeneic HCTs in the U.S. by Selected Disease





Abbreviations -

AML: Acute Myeloid Leukemia;

ALL: Acute Lymphoblastic Leukemia; MDS: Myelodysplastic Syndromes; MPN: Myeloproliferative Neoplasms; NHL: Non-Hodgkin Lymphoma;


HL: Hodgkin Lymphoma;

CML: Chronic Myeloid Leukemia; MM: Multiple Myeloma;

PCDs: Plasma Cell Disorders;

CLL: Chronic Lymphocytic Leukemia.

# Number of HCTs by Indications in the U.S., Pediatric, 2021





Abbreviations -

ALL: Acute Lymphoblastic Leukemia; AML: Acute Myeloid Leukemia;

HL: Hodgkin Lymphoma;

MDS: Myelodysplastic Syndromes;

MPN: Myeloproliferative Neoplasms;


CML: Chronic Myeloid Leukemia. NHL: Non-Hodgkin Lymphoma:

CLL: Chronic Lymphocytic Leukemia.

Non-malignant disease excludes Aplastic Anemia.

Pediatric: <18 years

# Number of HCTs by Indications in the U.S., Adult, 2021





Abbreviations -

PCDs: Plasma Cell Disorders;

AML: Acute Myeloid Leukemia; NHL: Non-Hodgkin Lymphoma; MDS: Myelodysplastic Syndromes;MPN: Myeloproliferative Neoplasms;

ALL: Acute Lymphoblastic Leukemia; HL: Hodgkin Lymphoma; CML: Chronic Myeloid Leukemia; CLL: Chronic Lymphocytic Leukemia. Non-malignant disease excludes Aplastic

Anemia. Adult: ≥18 years



## **Cancer Incidence in Puerto Rico**


Figure 2. Top ten cancer	sites (incidence)	by sex: Puerto F	Rico, 2016-2020
--------------------------	-------------------	------------------	-----------------

o <sup>™</sup> Male (N = 37,548)	%	AAPC <sup>2000-2019</sup>	<b>Premale (N = 34,221)</b>	%	AAPC <sup>2000-2019</sup>
Prostate	38.3	<b>1.7*</b>	Breast	30.5	<b>1.7*</b>
Colon and rectum	11.5	0.2	Colon and rectum	10.5	-0.1
Lung and bronchus	5.4	↓ -1.0*	Corpus and uterus, NOS	9.6	<b>1</b> 4.6*
Urinary bladder	4.4	0.1	Thyroid	9.5	<b>1</b> 9.0*
Non-Hodgkin lymphoma	3.9	↑ 1.8*	Lung and bronchus	4.0	0.4
Oral cavity and pharynx	3.5	↓ -0.7*	Non-Hodgkin lymphoma	3.9	<b>1</b> 2.1*
Liver and bile duct	3.5	↑ 1.9*	Cervix uteri	2.8	0.5
Kidney and renal pelvis	3.1	↑ 4.3*	Pancreas	2.5	↑ 3.1*
Leukemia	2.8	↑ 2.2* <b>(</b>	Leukemia	2.4	<b>1</b> 2.7*
Pancreas	2.6	↑ 2.2*	Ovary	2.3	<b>↑</b> 0.8*
Other sites	21.1		Other sites	21.9	

- According to the Puerto Rico Cancer Registry, during the 2016-2020 period, 71,769 persons were diagnosed with cancer in Puerto Rico.
- NHL comprises 3.9% of cancer cases in PR for males and 3.9% for females.
- Leukemia comprises 2.8% of cancer cases in PR for males and 2.4% for females.

## **BMT** related cancer cases in Puerto Rico

- Estimated Cases for year 2016-2020 derived from incidence rates per 100,000 persons (published by the PR Cancer Registry).
- NHL had the largest number of new BMT related cancer cases.



Dr. Luis Clavell



Dr. Maribel García

# **Pediatric BMT programs in Puerto Rico**

- Two main Pediatric BMT programs:
  - San Jorge Children's Hospital (autologous and allogeneic, Closed in 2019)
  - University Pediatric Hospital in Centro Medico (autologous and allogeneic)



- **97** transplants performed to 87 children and young adults
- 55 males and 32 females, aged between 12 months and 38 years
- Source of HSCs:
  - **52** autologous (5 BM, 47 PBSC)
  - 45 allogeneic (23 MRD BM, 18 MRD PBSC, 1 syngeneic PBSC, 4 Haploidentical BM)
- Diagnosis: Acute leukemia, chronic leukemia, MDS, aplastic anemia, histiocytosis, neuroblastoma, lymphomas, PNET, Wilms tumor, and desmoplastic round cell tumor
- HIMA-San Pablo Hospital Caguas, PR
  - Dr. John Guerra (4 Autologous, 1 Allogeneic)





# **Adult BMT programs in Puerto Rico**



- University District Hospital Centro Medico
  - Founded in **1997** by Dr. Justiniano Castro
  - Autologous HCT
  - Approximately 25 transplants per year





- HIMA-San Pablo Hospital Caguas, PR
  - Founded in **2010** by Dr. Norma Salgado Vila
  - Autologous HCT
  - Approximately 35 transplants per year (Total 453)





- Hospital Español Auxilio Mutuo San Juan, PR
  - Founded in 2015 by Dr. Alexis M. Cruz Chacón
  - Autologous HCT



# **Hematopoietic Stem Cell Collection and Processing**





 HSC collection, processing, cryopreservation and administration in Puerto Rico performed by the American Red Cross (ARC).



 ARC is the only provider of these services for all BMT Programs in Puerto Rico.







## HSCs from Puerto Rico Donors saved lives around the World



 Approximately 100 matched unrelated donors collected for NMPD during the year period from 2011 to 2020.



# The Road to Adult Allogeneic HCT for Puerto Rico

- Adult BMT Programs in Puerto Rico only performed Autologous HCT
  - Around 40 cases per year on each adult program
  - Adult patients in need for Allogeneic HCT must travel to USA
- In 2011 Moffitt Cancer Center BMT program (Tampa, FL) established a monthly clinic in Bayamon, Puerto Rico for initial evaluation of patients with indications for BMT (allogeneic and autologous)
  - Dr. Melissa Alsina and Dr. Leonel Ochoa Bayona
  - Patients still needed to travel to US to receive Allogeneic HCT







Allogeneic HCT was still a NECESSITY for Adult patients in PR

# A good reason to have Allogeneic HCT done locally in PR





1.6 million patients

**NO COVERAGE FOR BMT** 



\$340,000.00



\$450,000.00

# 2014: A Door Opened







# Why Hospital Auxilio Mutuo?

- One of Puerto Rico's biggest Hospitals.
- Successful solid organ transplant program.
- Accredited Histocompatibility and Immunogenic Lab.
- Medical faculty with over 700 specialists and subspecialists.
- Wide range of diagnostic and treatment services with multiple specialized centers and units in the same place.
- Significant population of patients with indications for BMT referred to Auxilio Cancer Center. RICAS

Optimal Institution to start an Allogeneic BMT Program

## **Collaboration with Moffitt Cancer Center**

- Counseling for design of BMT program with the standard of care.
- Education and training of BMT unit nurse manager and BMT coordinator.
- Assistance and counseling for development and implementation of BMT specific nursing educational curriculum and clinical competencies in our institution.
- Consult of difficult or challenging cases with team of experienced and renowned BMT physicians.







## **AUXILIO MUTUO BMT PROGRAM**

**OUR FIRST STEPS** 



Construction of BMT Unit Started

#### **March 2015**

Opening of BMT Unit
Started evaluation of BMT
Candidates at Clinic







#### October 2014

Training of Manager and Coordinatot at Moffitt

## May 2015

First Autologous HCT



5/27/15



## **AUXILIO MUTUO BMT PROGRAM**

OUR CRAZY DREAM CAME TRUE





## February 2017

MRD Allogeneic HCTs







#### **March 2018**

First Haploidentical HCT
First BM Harvest



3/23/18





## **AUXILIO MUTUO BMT PROGRAM**

JOINING FORCES TO BUILD A SOLID TEAM AND PREPARE FOR THE FUTURE





Multiple Myeloma Clinic



#### **June 2020**

BMT Ambulatory Clini Facility Inaugurated



BMT Infectious Diseases







#### March-May 2020

COVID-19 Pandemic
15 Autologous HCT
3 Allogeneic HCT

## **July 2020**

Dr. Cristian Rodríguez BMT-CI Specialist CART



#### October 2023

Or. Carlos Bachler

BMT-CI Specialist

CART, Research









TILL YEAR 2023

**478** TRANSPLANTS


359 AUTOLOGOUS


119 ALLOGENEIC

# **Total HCTs** by **Sex**, BMT-HAM 2015 – 2023

## **AUTOLOGOUS**

## **ALLOGENEIC**









# Total HCTs by Type, BMT-HAM 2015 – 2023





**Transplant Year** 







# **Total Allogeneic** HCTs by **Donor** and **Source** Type , BMT-HAM 2015 – 2023

## **DONOR TYPE**

## **SOURCE TYPE**










# **Total** Allogeneic HCTs by **Type**, BMT-HAM 2015 – 2023





**Transplant Year** 






# **Total** HCTs by **Age Group**, BMT-HAM 2015 – 2023

## **AUTOLOGOUS**


### **ALLOGENEIC**








# **Total Autologous** HCTs by **Age Group** and **Condition**, BMT-HAM 2015 – 2023



## **Total Allogeneic** HCTs by **Age Group** and **Condition**, BMT-HAM 2015 – 2023




# **Survival 2021-2022**

	2	021 Survival <sup>(</sup>	2%	2022 Survival %			
	+30 days	+100 days	+365 days	+30 days	+100 days	+365 days	
Auto HCT	52/52 = 100.0%	52/52 = 100.0%	52/52 = 100.0%	54/55 = 98.2%	54/55 = 98.2%	54/55 = 98.2%	
Allo HCT	14/17 = 82.3%	13/17 = 76.5%	9/17 = 52.7%	25/28 = 89.3%	24/28 = 85.7%	17/28 = 60.7%	
Total HCT	66/69 = 95.7%	65/69 = 94.2%	61/69 = 88.4%	79/83 = 95.2%	78/83 = 93.9%	70/83 = 84.3%	






# **Total Autologous** HCTs by **Municipality**, San Juan P.R. 2015 – 2023







# **Total Allogeneic** HCTs by **Municipality**, San Juan P.R. 2015 – 2023








# **Total** HCTs by **Healthcare Plan**, BMT-HAM 2015 – 2023

## **AUTOLOGOUS**

Y TERAPIA CELULAR

# 2% 28% 31% 32% Vital ■ Comercial ■ Medicare Advantage ■ VA


#### **ALLOGENEIC**






# 2024: Ten Years Later

YES, WE ARE STILL DREAMING












# POST ASCC





# Can we give CAR T cells in PR?



- 179 Auto-HCT
- 39 Allo-HCT (17 Haplo-T)
- >60% patients with Government Insurance
- Multi-disciplinary teams and infrastructures to manage logistics and patient care
- Robust quality processes and infrastructure








**Dr. Cristian Rodriguez Arocho** 







# REALITY: The road to CAR T in PR isn't an easy one.





In 2024: Can we still give CAR T cells in PR?

YES!!!

# Choose a job you love

and you will never have to work a day in your life





Caminante, son tus huellas
el camino y nada más;
Caminante, no hay camino,
se hace camino al andar.
Al andar se hace el camino,
y al volver la vista atrás
se ve la senda que nunca
se ha de volver a pisar.
Caminante no hay camino
sino estelas en la mar.









